Abstract
Neuroleptic malignant syndrome (NMS) is a rare disorder characterized by hyperthermia, elevated creatine phosphokinase, extrapyramidal effects, autonomic instability, altered level of consciousness and leukocytosis associated with neuroleptic and other psychotropic medications. There are no cases of NMS reported following stem cell transplantation. We describe two patients receiving autotransplants who developed NMS. With the common use of neuroleptic and other related psychotropic medications in the peri-transplant period and the associated physiologic stress of the procedure, we believe that NMS may be unrecognized and account for significant morbidity in this setting.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garrido, S., Chauncey, T. Neuroleptic malignant syndrome following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 21, 427–428 (1998). https://doi.org/10.1038/sj.bmt.1701093
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701093
Keywords
This article is cited by
-
Neurologic Complications of Transplantation
Neurocritical Care (2018)
-
Neuroleptic malignant syndrome following BMT
Bone Marrow Transplantation (2002)